Qiagen Stock - Deutsche Bank reiterates Buy rating before Q2 update

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 21:25 CET. Details in the imprint.

Qiagen (NL0012169213) is back on analyst screens after Deutsche Bank reiterated its Buy rating on the diagnostics specialist. According to a Deutsche Bank research note dated 06/17/2026, the bank expects second-quarter figures to come in broadly in line with guidance.

What Deutsche Bank highlights

Deutsche Bank Research analyst Jan Koch reaffirmed his Buy recommendation on Qiagen in a note published on 06/17/2026, ahead of the company’s second-quarter numbers. The bank expects results to broadly match management’s guidance for the year. A MarketScreener summary of the note states that the rating and positive stance were reiterated.

According to this summary, Qiagen continues to be seen as a structurally attractive player in molecular diagnostics and life science tools, benefiting from recurring consumables sales and a broad installed base of instruments. The note points to a supportive demand backdrop in clinical testing and research applications, despite a normalization from pandemic-driven peaks.

Operational lens on a Wednesday

From an operational perspective, Deutsche Bank expects Qiagen’s second-quarter performance to stay within its own guidance corridor, indicating no major surprise but a test of execution. The comment underlines that margins and cost discipline will be closely watched after recent investments in product platforms and automation.

In German trading on Xetra, Qiagen shares were quoted around EUR 32.12 on 06/17/2026 in the morning session, with the stock about 21.5% lower year-to-date, according to exchange data. The U.S.-listed shares on the New York Stock Exchange last closed at $37.22 on 06/16/2026.

What the company sells

Qiagen generates its revenue with so-called "Sample to Insight" solutions, which turn biological samples into actionable molecular information. A flagship product family is the QIAcuity digital PCR platform, used for highly sensitive detection and quantification of genetic material in research and clinical laboratories.

Where the stock trades today

The shares of Qiagen (NL0012169213) trade on the New York Stock Exchange at $37.22 as of 06/16/2026, 22:00 ET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.